Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) ≥18 and ≤35~* Established diagnosis of primary dysmenorrhea~* If of child-bearing potential must agree to use condoms for contraception during the entire screening period, treatment period, and post-treatment period until the final study visit, unless she or her partner are surgically sterilized~* Agree to stop using hormonal contraceptive (combined or progestin-only), or a non hormonal intrauterine device (IUD)~* Regular menstrual cycles ranging from 24 to 35 days in length~Exclusion Criteria:~* Any of the following contraindications to the use of contraceptive steroids including: presence or a history of venous or arterial thrombotic/thromboembolic events or cerebrovascular accident (stroke, history of migraine with focal neurological symptoms, diabetes mellitus with vascular involvement, severe or multiple risk factor(s) for venous or arterial thrombosis, severe dyslipoproteinemia, severe hypertension, pancreatitis or a history thereof if associated with severe hypertriglyceridaemia, presence or history of severe hepatic (liver) disease, including benign or malignant tumors, known or suspected sex steroid-influenced malignancies, and/or undiagnosed vaginal bleeding~* Pregnant or breastfeeding~* Secondary dysmenorrhea~* Has not had spontaneous menstruation following a delivery or abortion~* Participated in an investigational drug study within 30 days~* History of malignancy ≤5 years~* Documented abnormal cervical smear result within 6 months~* Use of recreational or illicit drugs~* Consumes \>2 alcoholic drinks per day or \>14 alcoholic drinks per week, or engages in binge drinking~* Allergy/sensitivity to ibuprofen, or any contraindication to its use, or has experienced asthma, urticaria, or allergic-type reactions after taking aspirin, or other nonsteroidal anti inflammatory drugs~* Has been sterilized using a fallopian tube occlusion device~* Is receiving, or has received sex hormones for any purpose other than contraception within 2 months or injectable hormonal contraception within 6 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- NOMAC-E2 700/300 mcg (Type: EXPERIMENTAL): NOMAC-E2 700/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
- NOMAC-E2 900/300 mcg (Type: EXPERIMENTAL): NOMAC-E2 900/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
- ENG-E2 100/300 mcg (Type: EXPERIMENTAL): ENG-E2 100/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
- ENG-E2 125/300 mcg (Type: EXPERIMENTAL): ENG-E2 125/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.

Based on this trial design, predict the completion outcome and termination type (if applicable).